Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;268(1):1-8.
doi: 10.1097/SLA.0000000000002672.

Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?

Jin He  1 , Alex B Blair  1 , Vincent P Groot  1 , Ammar A Javed  1 , Richard A Burkhart  1 , Georgios Gemenetzis  1 , Ralph H Hruban  2 , Kevin M Waters  2 , Justin Poling  2 , Lei Zheng  3 , Daniel Laheru  3 , Joseph M Herman  4 , Martin A Makary  1 , Matthew J Weiss  1 , John L Cameron  1 , Christopher L Wolfgang  1
Affiliations

Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?

Jin He et al. Ann Surg. 2018 Jul.

Abstract

Objectives: To describe the survival outcome of patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) who have a pathologic complete response (pCR) following neoadjuvant chemoradiation.

Background: Patients with BR/LA-PDAC are often treated with neoadjuvant chemoradiation in an attempt to downstage the tumor. Uncommonly, a pCR may result.

Methods: A retrospective review of a prospectively maintained database was performed at a single institution. pCR was defined as no viable tumor identified in the pancreas or lymph nodes by pathology. A near complete response (nCR) was defined as a primary tumor less than 1 cm, without nodal metastasis. Overall survival (OS) and disease-free survival (DFS) were reported.

Results: One hundred eighty-six patients with BR/LA-PDAC underwent neoadjuvant chemoradiation and subsequent pancreatectomy. Nineteen patients (10%) had a pCR, 29 (16%) had an nCR, and the remaining 138 (74%) had a limited response. Median DFS was 26 months in patients with pCR, which was superior to nCR (12 months, P = 0.019) and limited response (12 months, P < 0.001). The median OS of nCR (27 months, P = 0.003) or limited response (26 months, P = 0.001) was less than that of pCR (more than 60 months). In multivariable analyses pCR was an independent prognostic factor for DFS (HR = 0.45; 0.22-0.93, P = 0.030) and OS (HR=0.41; 0.17-0.97, P = 0.044). Neoadjuvant FOLFIRINOX (HR=0.47; 0.26-0.87, P = 0.015) and negative lymph node status (HR=0.57; 0.36-0.90, P = 0.018) were also associated with improved survival.

Conclusions: Patients with BR/LA-PDAC who had a pCR after neoadjuvant chemoradiation had a significantly prolonged survival compared with those who had nCR or a limited response.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
A) Kaplan-Meier estimates of overall survival in patients with BR/LA-PDAC treated with neoadjuvant chemoradiation followed by pancreatic resection based on histological response. B) Kaplan-Meier estimates of overall survival in patients with BR/LA-PDAC treated with neoadjuvant chemo-radiation followed by pancreatic resection based on histological response. pCR v nCR (P = 0.003), pCR v LR (P = 0.001), LR v nCR (P = 0.773).
FIGURE 2.
FIGURE 2.
Kaplan-Meier estimates of disease-free survival in patients with BR/LA-PDAC treated with neoadjuvant chemoradiation followed by pancreatic resection based on histological response. pCR v nCR (P = 0.019), pCR v LR (P < 0.001), LR v nCR (P = 0.768).
See this image and copyright information in PMC

Comment in

References

    1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. - PubMed
    1. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–348. - PMC - PubMed
    1. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024. - PubMed
    1. Hidalgo M Pancreatic cancer. N Engl J Med. 2010;362:1605–1617. - PubMed
    1. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267. - PMC - PubMed

MeSH terms